Investing.com -- Boston Scientific (NYSE:BSX) stock climbed over 1% in premarket trading Wednesday after the company raised its full-year earnings guidance, surpassing the consensus estimate.
Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.